Aurealis Therapeutics is a startup based in Switzerland, most recent round Series B, 4 tracked investors.
Aurealis Therapeutics is a company founded in 2018 headquartered in Switzerland. Its most recent tracked round is Series B. Brouky records 4 investors associated with the company.
Aurealis Therapeutics develops multi-target cell and gene therapies focused on treating chronic wounds, cancers, and inflammatory diseases using a proprietary platform to modulate tissue microenvironments.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.